Revised mechanism of hydroxyurea-induced cell cycle arrest and an improved alternative.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
15 Oct 2024
Historique:
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 7 10 2024
Statut: ppublish

Résumé

Replication stress describes endogenous and exogenous challenges to DNA replication in the S-phase. Stress during this critical process causes helicase-polymerase decoupling at replication forks, triggering the S-phase checkpoint, which orchestrates global replication fork stalling and delayed entry into G2. The replication stressor most often used to induce the checkpoint response in yeast is hydroxyurea (HU), a clinically used chemotherapeutic. The primary mechanism of S-phase checkpoint activation by HU has thus far been considered to be a reduction of deoxynucleotide triphosphate synthesis by inhibition of ribonucleotide reductase (RNR), leading to helicase-polymerase decoupling and subsequent activation of the checkpoint, facilitated by the replisome-associated mediator Mrc1. In contrast, we observe that HU causes cell cycle arrest in budding yeast independent of both the Mrc1-mediated replication checkpoint response and the Psk1-Mrc1 oxidative signaling pathway. We demonstrate a direct relationship between HU incubation and reactive oxygen species (ROS) production in yeast and human cells and show that antioxidants restore growth of yeast in HU. We further observe that ROS strongly inhibits the in vitro polymerase activity of replicative polymerases (Pols), Pol α, Pol δ, and Pol ε, causing polymerase complex dissociation and subsequent loss of DNA substrate binding, likely through oxidation of their integral iron-sulfur (Fe-S) clusters. Finally, we present "RNR-deg," a genetically engineered alternative to HU in yeast with greatly increased specificity of RNR inhibition, allowing researchers to achieve fast, nontoxic, and more readily reversible checkpoint activation compared to HU, avoiding harmful ROS generation and associated downstream cellular effects that may confound interpretation of results.

Identifiants

pubmed: 39374399
doi: 10.1073/pnas.2404470121
doi:

Substances chimiques

Hydroxyurea X6Q56QN5QC
Reactive Oxygen Species 0
Cell Cycle Proteins 0
Saccharomyces cerevisiae Proteins 0
Ribonucleotide Reductases EC 1.17.4.-
MRC1 protein, S cerevisiae 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2404470121

Subventions

Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : R00GM126143
Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : R35GM147105

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Alisa E Shaw (AE)

Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80525.

Mattias N Mihelich (MN)

Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80525.

Jackson E Whitted (JE)

Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80525.

Hannah J Reitman (HJ)

Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80525.

Adam J Timmerman (AJ)

Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80525.

Muhammad Tehseen (M)

Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal 23955, Saudi Arabia.

Samir M Hamdan (SM)

Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal 23955, Saudi Arabia.

Grant D Schauer (GD)

Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80525.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH